Tianjin Chase Sun Pharmaceutical Co., Ltd.
300026 · SZSE · China
chasesun.cnFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.42B, above the global median of $1.14B
- FinancialsAltman Z-Score 4.03: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.34%Below 5Y avg (0.66%)
Annual Rate
CNY 0.01Paid annual
Payout Ratio
100.0%High
Last Ex-Dividend
Jul 15, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
8.71BCNY1.42B · vs all stocks (USD)
Trailing P/E
290.00xRevenue (TTM)
3.90BCNY649.25M · vs all stocks (USD)
Profit Margin
0.66%Beta
0.0680xvs all stocks
52-Week Change
-19.67%vs all stocks
Market Capitalization
8.71BCNY1.42B · vs all stocks (USD)
Enterprise Value
7.48BCNY1.27B · vs all stocks (USD)
Trailing P/E
290.00xForward P/E
7.07xPrice to Sales (TTM)
2.23xPrice to Book (MRQ)
1.02xEnterprise to Revenue
1.92xEnterprise to EBITDA
19.83xGross Margin
56.51%Profit Margin
0.66%Operating Margin
3.12%Return on Assets (TTM)
0.73%Return on Equity (TTM)
0.28%Revenue (TTM)
3.90BCNY649.25M · vs all stocks (USD)
Revenue per Share (TTM)
1.92CNYUpdated Nov 22, 2026Quarterly Revenue Growth
-32.20%Gross Profit (TTM)
2.35BCNY383.69M · vs all stocks (USD)
EBITDA (TTM)
305.23MCNY45.72M · vs all stocks (USD)
Net Income (TTM)
25.77MCNY2.69M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
366.60%Operating Cash Flow (TTM)
769.10MCNY117.73M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
685.65MCNY117.51M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0100CNYUpdated Nov 22, 2026Trailing Annual Dividend Yield
0.34%vs all stocks
5-Year Average Dividend Yield
0.66%vs all stocks
Payout Ratio
100.00%Minority Interest (Equity)
154.66MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.0100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Operating Cash Flow
161.73MCNYFY2024 · Dec 31, 2024Free Cash Flow
-31.00MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
1.27BCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
22.95MCNYFY2024 · Dec 31, 2024Other Non-cash Items
68.15MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-10.92MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
81.56MCNYFY2024 · Dec 31, 2024Capital Expenditures
-192.73MCNYFY2024 · Dec 31, 2024Sale of Investments
6.79MCNYFY2024 · Dec 31, 2024Other Investing Activity
15.67MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-170.26MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
56.51MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-814.67MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-137.11MCNYFY2024 · Dec 31, 2024Other Financing Charges
-57.37MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-952.64MCNYFY2024 · Dec 31, 2024Shares Outstanding
3.00BSharesUpdated Nov 22, 2026Float Shares
1.91BSharesUpdated Nov 22, 2026% Held by Insiders
42.44%vs all stocks
% Held by Institutions
1.59%vs all stocks
Total Cash (MRQ)
1.70BCNY251.02M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5650CNYUpdated Nov 22, 2026Total Debt (MRQ)
348.17MCNY57.86M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0401xCurrent Ratio (MRQ)
4.98xBook Value per Share (MRQ)
2.85CNYUpdated Nov 22, 2026Total Assets
11.17BCNY1.67B · vs all stocks (USD)
Total Current Assets
6.15BCNYFY2024 · Dec 31, 2024Total Liabilities
2.37BCNYFY2024 · Dec 31, 2024Total Non-current Assets
5.02BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
745.41MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.62BCNYFY2024 · Dec 31, 2024Cash
1.26BCNYFY2024 · Dec 31, 2024Cash Equivalents
50.51MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
1.31BCNYFY2024 · Dec 31, 2024Accounts Receivable
2.66BCNYFY2024 · Dec 31, 2024Inventory
1.75BCNYFY2024 · Dec 31, 2024Accounts Payable
678.15MCNYFY2024 · Dec 31, 2024Short-term Debt
211.74MCNYFY2024 · Dec 31, 2024Other Current Liabilities
7.08MCNYFY2024 · Dec 31, 2024Long-term Debt
640.33MCNYFY2024 · Dec 31, 2024Common Stock (Book)
3.00BCNYFY2024 · Dec 31, 2024Retained Earnings
4.74BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
8.80BCNY1.32B · vs all stocks (USD)
52-Week Low
2.82CNYUpdated Nov 22, 202652-Week High
3.98CNYUpdated Nov 22, 202652-Week Change
-19.67%vs all stocks
Beta
0.0680xvs all stocks
50-Day MA
3.17CNYUpdated Nov 22, 2026200-Day MA
3.33CNYUpdated Nov 22, 2026Avg 10-Day Volume
28.21MSharesUpdated Nov 22, 2026Avg 30-Day Volume
34.21MSharesUpdated Nov 22, 2026Diluted EPS (TTM)
0.0100CNYUpdated Nov 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.00
Financial Health
Altman Z-Score 4.03: safe zoneNotable
Altman Z-Score: 4.03
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.42B, above the global median of $1.14BNotable
Market cap (USD): 1,422,070,766.743Global Median: 1,137,180,293.291
Revenue is $649.25M, above the global median of $566.17MNotable
Revenue (USD): 649,249,555.763Global Median: 566,172,992
Levered free cash flow is $117.51M, above the global median of $18.58MNotable
Levered free cash flow (USD): 117,506,715.2Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule